antiparkinson/pykinimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 46 rezultatus

Antiparkinsonian effects of BAM-1110, a novel ergoline derivative, in MPTP-treated cynomolgus monkeys.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BAM-1110 [(5R,8R,10R)-6-methyl-8-(1,2,4-triazol-l-ylmethyl) ergoline maleate] is a newly synthesized dopamine agonist that produces little anorexic side effects (nausea and vomiting). The current study examines the effects of BAM-1110 on parkinsonian symptoms in

Antiparkinson prodrugs.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is essentially symptomatic, and L-Dopa (LD), the direct precursor of dopamine(DA), is the treatment of choice in more advanced

The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

CQA 206-291, a new D2 dopamine receptor agonist with a biphasic dopaminergic profile, was given to six patients with idiopathic Parkinson's disease after overnight drug withdrawal. With incremental single oral doses of CQA, a dose-related, clinically significant, and prolonged antiparkinsonian

Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which

An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The D2 dopamine agonist piribedil is not widely used in the treatment of Parkinson's disease because it was thought to be effective mainly on parkinsonian tremor and to produce a high incidence of peripheral side effects, particular nausea. In this study, we used

The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

UNASSIGNED This case report describes a patient with known idiopathic Parkinson's disease, being managed with transdermal rotigotine, whose refractory nausea and vomiting was successfully controlled with subcutaneous levomepromazine. No drug-induced extrapyramidal side effects emerged. UNASSIGNED A

A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND As Parkinson's disease (PD) progresses,despite optimized pharmacotherapy, patients experience more frequent fluctuations between symptomatic improvement ("on" times) and the return of motor features ("off" times). Apomorphine, the first injectable dopamine agonist available in the United

Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To compare the tremorlytic properties of pramipexole, a non-ergoline dopamine agonist to those of placebo as add on medication in patients with Parkinson's disease. METHODS Eighty four patients with early or advanced Parkinson's disease and marked, drug resistant tremor under a stable and

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

CONCLUSIONS The semisynthetic ergotine dopamine agonist pergolide has demonstrated activity at pre- and postsynaptic dopamine D2 receptors in vitro and in vivo animal studies. However, unlike other dopamine agonists such as bromocriptine, pergolide also has agonist activity at dopamine D1 receptors.

Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

During a long-term double-blind study, which began February 1985, we have treated 16 patients with Morbus Parkinson or Parkinson's syndrome with deprenyl or identically appearing placebo tablets. The aim of the study is to ascertain whether a reduction of other antiparkinsonian medication,

Rapid intravenous loading of levodopa for human research: clinical results.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Levodopa has several advantages as a pharmacological challenge agent for human neuroscience research. Exogenous levodopa changes striatal neuronal activity and increases extracellular dopamine concentrations, and with adequate inhibition of peripheral metabolism levodopa does not change mean

Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE A literature evaluation of antidopaminergic therapies in patients with Parkinson's disease (PD) who have developed psychosis, nausea, vomiting, and hiccups was conducted. CONCLUSIONS Complications associated with the use of antiparkinsonian drugs make PD management more difficult given the

[Application of the common marmoset to pharmacological studies].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Application of the common marmoset to pharmacological studies was reviewed, especially employment of the animal as a model of Parkinson's disease were presented. The common marmoset is one of the New World monkeys with a body weight of 300-350 g. It is small enough to be easily handled and to be

Adverse effects in the treatment of Parkinson's disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral

[Apomorphine in off state--clinical experience].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Apomorphine, a non-ergot derivative, is a potent, directly acting dopamine receptor agonist with high affinity to D4, lower to D2, D3, D5, the lowest to D1-like dopamine receptors as well as to serotonin and adrenoreceptors. Subcutaneous apomorphine is currently used in Parkinson's disease as an

Ankstesnis
1
2
3
4
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais